153 related articles for article (PubMed ID: 9551890)
1. Rejection of allogeneic and syngeneic but not MHC class I-deficient tumor grafts by MHC class I-deficient mice.
Freland S; Chambers BJ; Andersson M; Van Kaer L; Ljunggren HG
J Immunol; 1998 Jan; 160(2):572-9. PubMed ID: 9551890
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of natural killer cell-mediated bone marrow graft rejection by allogeneic major histocompatibility complex class I, but not class II molecules.
Ohlén C; Höglund P; Sentman CL; Carbone E; Ljunggren HG; Koller B; Kärre K
Eur J Immunol; 1995 May; 25(5):1286-91. PubMed ID: 7774631
[TBL] [Abstract][Full Text] [Related]
3. A nonclassical MHC class I molecule restricts CTL-mediated rejection of a syngeneic melanoma tumor.
Chiang EY; Stroynowski I
J Immunol; 2004 Oct; 173(7):4394-401. PubMed ID: 15383569
[TBL] [Abstract][Full Text] [Related]
4. Fine tuning of natural killer cell specificity and maintenance of self tolerance in MHC class I-deficient mice.
Salcedo M; Andersson M; Lemieux S; Van Kaer L; Chambers BJ; Ljunggren HG
Eur J Immunol; 1998 Apr; 28(4):1315-21. PubMed ID: 9565371
[TBL] [Abstract][Full Text] [Related]
5. NK cell tolerance in mixed allogeneic chimeras.
Zhao Y; Ohdan H; Manilay JO; Sykes M
J Immunol; 2003 Jun; 170(11):5398-405. PubMed ID: 12759414
[TBL] [Abstract][Full Text] [Related]
6. Rejection of tumors in mice with severe combined immunodeficiency syndrome determined by the major histocompatibility complex. Class I expression on the graft.
Glas R; Waldenström M; Höglund P; Klein G; Kärre K; Ljunggren HG
Cancer Res; 1995 May; 55(9):1911-6. PubMed ID: 7728758
[TBL] [Abstract][Full Text] [Related]
7. Rejection of grafts with no H-2 disparity in TAP1 mutant mice: CD4 T cells are important effector cells and self H-2b class I molecules are target.
Suárez IM; Benvenutti LA; Noronh I; Van Kaer L; Kalil J; Coelho V
Transpl Immunol; 2002 May; 9(2-4):101-10. PubMed ID: 12180815
[TBL] [Abstract][Full Text] [Related]
8. Perforin-dependent cytolytic responses in beta2-microglobulin-deficient mice.
Smyth MJ; Snook MB
Cell Immunol; 1999 Aug; 196(1):51-9. PubMed ID: 10486155
[TBL] [Abstract][Full Text] [Related]
9. Development and antigen specificity of CD8+ cytotoxic T lymphocytes in beta 2-microglobulin-negative, MHC class I-deficient mice in response to immunization with tumor cells.
Apasov SG; Sitkovsky MV
J Immunol; 1994 Mar; 152(5):2087-97. PubMed ID: 8133027
[TBL] [Abstract][Full Text] [Related]
10. Analysis of graft-versus-host disease (GVHD) and graft rejection using MHC class I-deficient mice.
Shenoy S; Desch K; Duffy B; Thorson P; Mohanakumar T
Clin Exp Immunol; 1998 May; 112(2):188-95. PubMed ID: 9649180
[TBL] [Abstract][Full Text] [Related]
11. Autoreactivity to self H-2Kb peptides in TAP1 mice. Intravenous administration of H-2Kb class I-derived peptides induces long-term survival of grafts from C57BL/6 donors.
Marrero I; Benvenutti LA; Kalil J; Coelho V
Immunology; 2005 Aug; 115(4):484-94. PubMed ID: 16011517
[TBL] [Abstract][Full Text] [Related]
12. Beta2-microglobulin-deficient NK cells show increased sensitivity to MHC class I-mediated inhibition, but self tolerance does not depend upon target cell expression of H-2Kb and Db heavy chains.
Höglund P; Glas R; Ménard C; Kåse A; Johansson MH; Franksson L; Lemmonier F; Kärre K
Eur J Immunol; 1998 Jan; 28(1):370-8. PubMed ID: 9485216
[TBL] [Abstract][Full Text] [Related]
13. Apparent split tolerance of CD8+ T cells from beta 2-microglobulin-deficient (beta 2m-/-) mice to syngeneic beta 2m+/+ cells.
Jhaver KG; Rao TD; Frey AB; Vukmanović S
J Immunol; 1995 Jun; 154(12):6252-61. PubMed ID: 7759863
[TBL] [Abstract][Full Text] [Related]
14. Beta 2M-/- knockout mice contain low levels of CD8+ cytotoxic T lymphocyte that mediate specific tumor rejection.
Lamousé-Smith E; Clements VK; Ostrand-Rosenberg S
J Immunol; 1993 Dec; 151(11):6283-90. PubMed ID: 8245467
[TBL] [Abstract][Full Text] [Related]
15. Rejection of grafts without histocompatibility antigen disparity by TAP1-/- mice: a role for CD4+ T cells.
Marrero I; Benvenutti LA; Noronha I; Kalil J; Coelho V
Transplant Proc; 2004 May; 36(4):999-1000. PubMed ID: 15194347
[TBL] [Abstract][Full Text] [Related]
16. MHC Class I Expression by Donor Hematopoietic Stem Cells Is Required to Prevent NK Cell Attack in Allogeneic, but Not Syngeneic Recipient Mice.
Hirata Y; Li HW; Takahashi K; Ishii H; Sykes M; Fujisaki J
PLoS One; 2015; 10(11):e0141785. PubMed ID: 26544200
[TBL] [Abstract][Full Text] [Related]
17. MHC class I expression and CD8+ T cell development in TAP1/beta 2-microglobulin double mutant mice.
Ljunggren HG; Van Kaer L; Sabatine MS; Auchincloss H; Tonegawa S; Ploegh HL
Int Immunol; 1995 Jun; 7(6):975-84. PubMed ID: 7577806
[TBL] [Abstract][Full Text] [Related]
18. Generation of CD8+ T cells specific for transporter associated with antigen processing deficient cells.
Wolpert EZ; Petersson M; Chambers BJ; Sandberg JK; Kiessling R; Ljunggren HG; Kärre K
Proc Natl Acad Sci U S A; 1997 Oct; 94(21):11496-501. PubMed ID: 9326638
[TBL] [Abstract][Full Text] [Related]
19. Differential reactivity of residual CD8+ T lymphocytes in TAP1 and beta 2-microglobulin mutant mice.
Ljunggren HG; Van Kaer L; Ashton-Rickardt PG; Tonegawa S; Ploegh HL
Eur J Immunol; 1995 Jan; 25(1):174-8. PubMed ID: 7843229
[TBL] [Abstract][Full Text] [Related]
20. Deficiency of transporter for antigen presentation (TAP) in tumor cells allows evasion of immune surveillance and increases tumorigenesis.
Johnsen AK; Templeton DJ; Sy M; Harding CV
J Immunol; 1999 Oct; 163(8):4224-31. PubMed ID: 10510359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
